Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 2/3 1

Status

Completed 3Terminated 1Active not recruiting 1

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 1484Neoplasms 1101Carcinoma, Non-Small-Cell Lung 918Prostatic Neoplasms 802Multiple Myeloma 586Colorectal Neoplasms 535Leukemia, Myeloid, Acute 505Lung Neoplasms 489Lymphoma 455Melanoma 454Neoplasm Metastasis 451Lymphoma, Non-Hodgkin 416Leukemia 409Leukemia, Lymphocytic, Chronic, B-Cell 366Ovarian Neoplasms 357Pancreatic Neoplasms 338Precursor Cell Lymphoblastic Leukemia-Lymphoma 334Recurrence 315Head and Neck Neoplasms 298Lymphoma, Follicular 297Myelodysplastic Syndromes 282Carcinoma, Renal Cell 272Glioblastoma 266Brain Neoplasms 265Hodgkin Disease 260Lymphoma, Large B-Cell, Diffuse 255Carcinoma, Hepatocellular 241Lymphoma, Mantle-Cell 219Squamous Cell Carcinoma of Head and Neck 214Stomach Neoplasms 208

Interventions

Paclitaxel 2trametinib 1liposomal doxorubicin 1Topotecan 1Taxes 1Tamoxifen 1Letrozole 1Doxorubicin 1Diphenhydramine 1Dexamethasone 1Cimetidine 1AZD 6244 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Has results × Cystadenocarcinoma, Serous × Clear all
NCT02101788 2025-11-13

Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer

National Cancer Institute (NCI)

Phase 2/3 Completed
260 enrolled 20 charts

Cystadenocarcinoma, Serous

NCT00551070 2020-12-03

Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer

National Cancer Institute (NCI)

Phase 2 Completed
52 enrolled 11 charts

Cystadenocarcinoma, Serous

NCT00515073 2014-07-03

Papillary Serous Carcinoma of the Endometrium

M.D. Anderson Cancer Center

Phase 2 Completed
30 enrolled 5 charts
Gynecologic

Endometrial Neoplasms, Cystadenocarcinoma, Serous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡